Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mineralys Therapeutics, Inc.

16.73
-0.0200-0.12%
Post-market: 16.790.0600+0.36%19:56 EDT
Volume:882.69K
Turnover:14.79M
Market Cap:1.05B
PE:-4.57
High:17.29
Open:16.43
Low:16.32
Close:16.75
Loading ...

Mineralys Therapeutics Rises Ahead of Hypertension-Drug Trial Data

Dow Jones
·
08 Mar

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

GlobeNewswire
·
08 Mar

Q4 2024 Mineralys Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
13 Feb

Mineralys Therapeutics Inc (MLYS) Q4 2024 Earnings Call Highlights: Navigating Increased ...

GuruFocus.com
·
13 Feb

Mineralys Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
12 Feb

Mineralys Therapeutics Inc - Explore-Ckd Phase 2 Trial Enrollment Completed, Topline Data Expected Q2 2025

THOMSON REUTERS
·
12 Feb

Mineralys Therapeutics Inc Qtrly Shr Loss $0.98

THOMSON REUTERS
·
12 Feb

Mineralys Therapeutics Q4 EPS $(0.98) Beats $(1.04) Estimate

Benzinga
·
12 Feb

Mineralys Therapeutics FY Operating Income USD -192.403 Million

THOMSON REUTERS
·
12 Feb

Mineralys Therapeutics FY Operating Expenses USD 192.403 Million

THOMSON REUTERS
·
12 Feb

Mineralys Therapeutics FY EPS USD -3.66

THOMSON REUTERS
·
12 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
12 Feb

Mineralys Therapeutics Inc expected to post a loss of $1.08 a share - Earnings Preview

Reuters
·
10 Feb

Mineralys Completes Enrollment in Mid-Stage Hypertension Trial

MT Newswires Live
·
05 Feb

Mineralys Therapeutics completes enrollment in Explore-CKD Phase 2 trial

TIPRANKS
·
04 Feb

Mineralys Therapeutics Inc - to Share Topline Data From Explore-Ckd Trial in Q2 2025

THOMSON REUTERS
·
04 Feb